Cladribine



General

Pronunciation

(KLA dri been)

Indications

Use: Labeled Indications

Treatment of active hairy cell leukemia

Contraindications

Hypersensitivity to cladribine or any component of the formulation

ALERT: U.S. Boxed Warning

Experienced physician:

Cladribine should be administered under the supervision of a qualified health care provider experienced in the use of antineoplastic therapy.

Bone marrow suppression:

Anticipate suppression of bone marrow function. This is usually reversible and appears to be dose dependent.

Neurotoxicity:

Serious neurological toxicity (including irreversible paraparesis and quadriparesis) has been reported in patients who received cladribine by continuous infusion at high doses (4 to 9 times the recommended dose for hairy cell leukemia). Neurologic toxicity appears to demonstrate a dose relationship; however, severe neurological toxicity has been reported rarely following treatment with standard cladribine dosing regimens.

Renal toxicity:

Acute nephrotoxicity has been observed with high doses of cladribine (4 to 9 times the recommended dose for hairy cell leukemia), especially when given concomitantly with other nephrotoxic agents/therapies.

Subscribe to Access Full Content

Sign Up for a 10-Day Free Trial

Sign up for a 10-day FREE Trial now and receive full access to all content.

×